{"id":9765,"date":"2026-01-15T23:02:35","date_gmt":"2026-01-15T23:02:35","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2026\/01\/15\/jpm-2026-day-4-top-stories-regeneron-fda-ipos-jnj\/"},"modified":"2026-01-15T23:02:35","modified_gmt":"2026-01-15T23:02:35","slug":"jpm-2026-day-4-top-stories-regeneron-fda-ipos-jnj","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2026\/01\/15\/jpm-2026-day-4-top-stories-regeneron-fda-ipos-jnj\/","title":{"rendered":"STAT+: On Day 4 of JPM,\u00a0a chat with Regeneron\u2019s George Yancopoulos, an IPO forecast, and all eyes on J&amp;J"},"content":{"rendered":"\n<div>STAT+: On Day 4 of JPM,\u00a0a chat with Regeneron\u2019s George Yancopoulos, an IPO forecast, and all eyes on J&#038;J<\/div>\n<p> \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>This is the online version of The Readout, STAT\u2019s flagship biotech newsletter<\/em>.<em>\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get it in your inbox.<\/em><\/p>\n<p>We have made it! And so have you. This is Adam, Elaine, Matt, and Allison preparing to sign off from JPM26.<\/p>\n<p>And yet \u2014 we have one closing act. Join us at 1 p.m. ET tomorrow for a\u00a0<a href=\"https:\/\/www.statnews.com\/event\/jpm-2026-stat-recap\/\" target=\"_blank\" rel=\"noreferrer noopener\">virtual recap<\/a>\u00a0of the conference, where we\u2019ll talk about what we learned about the state of biotech, and what it portends for the year ahead.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2026\/01\/15\/jpm-2026-day-4-top-stories-regeneron-fda-ipos-jnj\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Allison DeAngelis, Matthew Herper, Adam Feuerstein, and Elaine Chen<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2026\/01\/15\/jpm-2026-day-4-top-stories-regeneron-fda-ipos-jnj\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: On Day 4 of JPM,\u00a0a chat with Regeneron\u2019s George Yancopoulos, an IPO forecast, and all eyes on J&#038;J This is the online version of The Readout, STAT\u2019s flagship biotech newsletter.\u00a0Sign up\u00a0to get it in your inbox. We have made it! And so have you. This is Adam, Elaine, Matt, and Allison preparing to sign [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2146,4611,4113,4572,2155,4612,2152],"tags":[2150],"class_list":["post-9765","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-fda","category-immunotherapy","category-johnson-johnson","category-jpm","category-pharmaceuticals","category-regeneron","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/9765"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=9765"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/9765\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=9765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=9765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=9765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}